Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, Isenberg D, Griffiths B, Lecky B, Chakravarty K, Winer J, Danko K, Cooper RG, White-Alao B, Scott DL. Ibrahim F, et al. Among authors: choy e. Rheumatology (Oxford). 2015 Jun;54(6):1050-5. doi: 10.1093/rheumatology/keu442. Epub 2014 Nov 27. Rheumatology (Oxford). 2015. PMID: 25433040 Free PMC article. Clinical Trial.
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.
Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium; Symmons DP, Lunt M; British Society for Rheumatology Biologics Register. Hyrich KL, et al. Rheumatology (Oxford). 2009 Oct;48(10):1323-7. doi: 10.1093/rheumatology/kep242. Epub 2009 Aug 25. Rheumatology (Oxford). 2009. PMID: 19706737 Free PMC article. Clinical Trial.
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Galloway JB, et al. Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31. Rheumatology (Oxford). 2011. PMID: 20675706 Free PMC article.
Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bechman K, Halai K, Yates M, Norton S, Cope AP; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Contributors Group; Hyrich KL, Galloway JB. Bechman K, et al. Arthritis Rheumatol. 2021 Oct;73(10):1800-1809. doi: 10.1002/art.41754. Epub 2021 Aug 17. Arthritis Rheumatol. 2021. PMID: 33844458
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP; British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Dixon WG, et al. Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129. Arthritis Care Res (Hoboken). 2010. PMID: 20535785 Free PMC article.
603 results